United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,258 shares of the stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $122.08, for a total value of $153,576.64. Following the completion of the transaction, the chief executive officer now owns 2,327 shares of the company’s stock, valued at approximately $284,080.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Corporation (UTHR) traded down 0.18% during midday trading on Friday, hitting $120.79. The company had a trading volume of 843,120 shares. The stock has a 50 day moving average price of $129.05 and a 200-day moving average price of $129.99. The stock has a market capitalization of $5.25 billion, a PE ratio of 14.01 and a beta of 1.52. United Therapeutics Corporation has a 52 week low of $110.90 and a 52 week high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by ($4.86). United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The business had revenue of $444.60 million for the quarter, compared to analyst estimates of $391.53 million. During the same period in the prior year, the company earned $4.42 earnings per share. The company’s quarterly revenue was up 7.8% on a year-over-year basis. On average, equities analysts predict that United Therapeutics Corporation will post $10.09 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/09/15/united-therapeutics-corporation-uthr-ceo-martine-a-rothblatt-sells-1258-shares.html.

Large investors have recently made changes to their positions in the stock. Comerica Bank increased its position in United Therapeutics Corporation by 1.3% during the 2nd quarter. Comerica Bank now owns 35,249 shares of the biotechnology company’s stock valued at $4,635,000 after buying an additional 458 shares in the last quarter. JPMorgan Chase & Co. increased its position in United Therapeutics Corporation by 1.8% during the 1st quarter. JPMorgan Chase & Co. now owns 122,497 shares of the biotechnology company’s stock valued at $16,583,000 after buying an additional 2,223 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in United Therapeutics Corporation during the 2nd quarter valued at about $5,256,000. Clarity Capital KCPS Ltd. acquired a new position in United Therapeutics Corporation during the 1st quarter valued at about $230,000. Finally, River & Mercantile Asset Management LLP acquired a new position in United Therapeutics Corporation during the 2nd quarter valued at about $908,000.

A number of equities analysts have issued reports on the company. BidaskClub downgraded United Therapeutics Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of United Therapeutics Corporation in a report on Friday, September 8th. ValuEngine downgraded United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Zacks Investment Research cut United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Finally, Jefferies Group LLC reissued a “sell” rating and issued a $105.00 target price on shares of United Therapeutics Corporation in a research note on Friday, July 14th. Six equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $134.50.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.